WO2000030639A1 - Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems - Google Patents

Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems Download PDF

Info

Publication number
WO2000030639A1
WO2000030639A1 PCT/EP1999/008734 EP9908734W WO0030639A1 WO 2000030639 A1 WO2000030639 A1 WO 2000030639A1 EP 9908734 W EP9908734 W EP 9908734W WO 0030639 A1 WO0030639 A1 WO 0030639A1
Authority
WO
WIPO (PCT)
Prior art keywords
azabicyclo
exo
ethyl
fluorophenyl
heptan
Prior art date
Application number
PCT/EP1999/008734
Other languages
English (en)
French (fr)
Inventor
Gerd Steiner
Rainer Munschauer
Gerhard Gross
Martin Traut
Liliane Unger
Hans-Jürgen Teschendorf
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0104416A priority Critical patent/HUP0104416A3/hu
Priority to BR9915589-3A priority patent/BR9915589A/pt
Priority to IL14318199A priority patent/IL143181A0/xx
Priority to AU17753/00A priority patent/AU1775300A/en
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Priority to SK711-2001A priority patent/SK7112001A3/sk
Priority to CA002352526A priority patent/CA2352526A1/en
Priority to EP99960974A priority patent/EP1133293A1/de
Priority to PL99348758A priority patent/PL348758A1/xx
Priority to KR1020017006445A priority patent/KR20010080535A/ko
Priority to JP2000583522A priority patent/JP2002530333A/ja
Publication of WO2000030639A1 publication Critical patent/WO2000030639A1/de
Priority to NO20012538A priority patent/NO20012538L/no
Priority to BG105549A priority patent/BG105549A/xx
Priority to HR20010472A priority patent/HRP20010472A2/hr
Priority to HK02102768.4A priority patent/HK1040933A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Definitions

  • N-substituted azabicycloalkane derivatives for the treatment of diseases of the central nervous system
  • N-substituted azabicycloalkane derivatives are already known as neuroleptics (WO 95/13279, WO 95/15327, WO 96/04272, US 5,475,105, US 5,521,209, US 5,616,705, US 5,753,690). It has now been found that these substances are also suitable for combating addiction disorders and other disorders of the central nervous system.
  • the invention relates to the use of N-substituted 3-azabicycloalkane derivatives of the formula I.
  • B is a 4-, 5- or 6-ring which can contain a double bond
  • R 1 is a mono- or disubstituted phenyl, naphthyl or optionally substituted by halogen atoms, C 4 alkyl, trifluoromethyl, hydroxy, C 4 alkoxy, amino, monomethylamino, dimethylamino, cyano or nitro groups Phenanthryl or thienyl group,
  • n the number 0, 1, 2, 3 or 4 and
  • R 2 denotes a naphthyl group which is optionally substituted by one or two halogen atoms or one of the following radicals: R3 0 R8 C R5 NR 6 CR 7 NR 6 - so 2 - (CJS
  • R 3 represents a hydrogen atom, a hydroxyl group or a phenyl radical optionally substituted by a fluorine, chlorine or bromine atom,
  • R 4 represents a hydrogen atom
  • R 3 and R 4 together represent an oxygen atom
  • R 5 is optionally mono- or disubstituted phenyl by fluorine, chlorine or bromine atoms or hydroxyl, nitro, amino, C ⁇ _ 4 -alkanoylamino, C ⁇ - 4 alkyl, amino, C ⁇ _ 4 alkyl or methoxy groups , Naphthyl or thienyl group means
  • R 6 represents a hydrogen atom or a methyl group
  • R 7 is a phenyl mono- or disubstituted by fluorine, chlorine or bromine atoms or by C 4 alkyl, hydroxyl, methoxy, nitro, cyano, trifluoromethyl, amino or di-C 4 alkylamino groups -, naphthyl, benzofuryl, benzothienyl, thienyl, indolyl, N-methylindolyl or indenyl group or a C 3 _ 7 -cycloalkyl group,
  • R 8 is a hydrogen atom or a fluorine or chlorine atom or a C 4 alkyl, methoxy or amino group
  • R 9 represents a hydrogen atom or a methyl group
  • R 10 represents a hydrogen atom or a methyl group
  • R 9 and R 10 together with the ring carbon atom represent a spirocyclopropane ring
  • R 11 is a hydrogen atom, a hydroxy, -CC 4 alkyl or
  • X and Y are carbon atoms, CH, CH 2 , NH or -CC alkyl-N groups or nitrogen atoms,
  • Z is a direct bond, a CO group, CS group or one
  • A is a hydrogen tom, a hydroxy, amino, mercapto,
  • A denotes a C 3 -C 4 -alkylene group linked to Y, which may contain one or two non-cumulative double bonds and in which a CH or CH 2 group is replaced by a nitrogen or sulfur atom or an NH or N-CH 3 - Group can be replaced and the ring either by a fluorine or chlorine atom or a methyl, methoxy, nitro or amino group monosubstituted or in the case of a benzene ring this by fluorine or chlorine atoms or methyl, trifluoromethyl, nitro, hydroxyl, methoxy, amino, monomethyl or dimethylamino groups can be mono-, di- or tri-substituted,
  • ring containing X, Y and Z on nitrogen atom No. 1 has a C ⁇ -C 4 -alkyl, allyl or benzyl group and can contain 1 to 3 non-cumulative double bonds,
  • Addictive substances can be:
  • Opioids such as morphine or heroin, nicotine, alcohol,
  • Substances that interact with the benzodiazepine-receptor complex sedatives or tranquilizers, such as the benzodiazepines.
  • cocaine or amphetamine and amphetamine-like substances are particularly suitable as addictive substances.
  • the compounds of formula I can be used both in the form of their racemates and their optical isomers.
  • the compounds can be administered orally or parenterally, intravenously or intramuscularly in the usual way.
  • the dosage depends on the age, condition and weight of the patient and on the type of application.
  • the daily dose of active substance is between approximately 1 and 100 mg / kg body weight when administered orally and between 0.1 and 10 mg / kg body weight when administered parenterally.
  • the compounds can be used in common galenical application forms in solid or liquid form, for example as tablets, film tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are produced in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants 10 and / or propellants (see H. Sucker et al:
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 1 to 99% by weight.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)

Abstract

Es wird die Verwendung von N-substituierten 3-Azabicycloalkan-Derivaten der Formel (I), worin B, R1, R2 und n die in der Beschreibung angegebene Bedeutung haben, zur Bekämpfung von Sucherkrankungen und anderen Erkrankungen des zentralen Nervensystems beschrieben.

Description

Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
Beschreibung
N-substituierte Azabicycloalkan-Derivate sind bereits als Neuroleptika bekannt (WO 95/13279, WO 95/15327, WO 96/04272, US 5.475.105, US 5.521.209, US 5.616.705, US 5.753.690). Es wurde nun gefunden, daß sich diese Substanzen auch zur Bekämpfung von Suchterkrankungen und anderen Erkrankungen des zentralen Nervensystems eignen.
Gegenstand der Erfindung ist die Verwendung von N-substituierten 3-Azabicycloalkan-Derivaten der Formel I
Figure imgf000003_0001
worin
B ein 4-, 5- oder 6-Ring ist, der eine Doppelbindung enthalten kann, ist,
R1 eine gegebenenfalls durch Halogenatome, Cι_4-Alkyl, Trifluor- methyl-, Hydroxy-, Cι-4-Alkoxy-, Amino-, Monomethylamino-, Dimethylamino- , Cyano- oder Nitrogruppen mono- oder disubstituierte Phenyl-, Naphthyl-, Phenanthryl-, oder Thienylgruppe bedeutet,
n die Zahl 0, 1, 2, 3 oder 4 bedeutet und
R2 eine gegebenenfalls durch ein oder zwei Halogenatome substituierte Naphthylgruppe oder einen der folgenden Reste bedeutet : R3 0 R8 C R5 NR6 C R7 NR6 — so2 — ( CJS
R4
Figure imgf000004_0001
worin
R3 ein Wasserstof fatom, eine Hydroxygruppe oder einen gegebenenfalls durch ein Fluor- , Chlor- oder Bromatom substituierten Phenylrest darstellt ,
R4 ein Wasserstoffatom bedeutet oder
R3 und R4 zusammen ein Sauerstoffato darstellen, R5 eine gegebenenfalls durch Fluor-, Chlor- oder Bromatome oder Hydroxy- , Nitro-, Amino-, Cι_4-Alkanoylamino-, Cι-4-Alkyl- amino-, Cι_4-Alkyl- oder Methoxygruppen mono- oder disubstituierte Phenyl-, Naphthyl- oder Thienylgruppe bedeu- tet,
R6 ein Wasserstoffatom oder eine Methylgruppe darstellt,
R7 eine durch Fluor-, Chlor- oder Bromatome oder durch Cι_4-Alkyl-, Hydroxy-, Methoxy-, Nitro-, Cyano-, Trifluor- methyl-, Amino- oder Di-Cι_4-Alkylaminogruppen mono- oder disubstituierte Phenyl-, Naphthyl-, Benzofuryl-, Benzo- thienyl-, Thienyl-, Indolyl-, N-Methylindolyl- oder Indenyl- gruppe oder eine C3_7-Cycloalkylgruppe bedeutet,
R8 ein Wasserstoffatom oder ein Fluor- oder Chloratom oder eine Cι_4-Alkyl-, Methoxy- oder Aminogruppe ist,
R9 ein Wasserstoffatom oder eine Methylgruppe darstellt und
R10 ein Wasserstoffatom oder eine Methylgruppe oder
R9 und R10 zusammen mit dem Ring-Kohlenstoffatom einen Spirocyclo- propanring darstellen,
R11 ein Wasserstoffatom, eine Hydroxy-, Cι-C4-Alkyl- oder
Cι-C4-Alkoxygruppe ist, oder zusammen mit dem benachbarten Kohlenstoffatom eine C=0- oder C=S-Gruppe bedeutet,
X und Y Kohlenstoffatome, CH-, CH2-, NH- oder Cι-C-Alkyl-N- Gruppen oder Stickstoffatome bedeuten,
Z eine direkte Bindung, eine CO-Gruppe, CS-Gruppe oder eine
CH- bzw. CH2-Gruppe, in denen ein Wasserstoffatom gegen eine Hydroxy-, Amino- oder Cι-C4~Alkoxygruppe oder ein Halogenatom ausgetauscht sein kann, darstellt, und
A ein Wasserstoff tom, eine Hydroxy-, Amino-, Mercapto-,
C1-C4-Alkylamino-, Di-Cι-C4-alkylamino-, Cι~C4-Alkylthio- oder C-C4-Alkoxygruppe oder zusammen mit dem benachbarten Kohlenstoffatom eine C=0-Gruppe bedeutet, oder
A eine mit Y verknüpfte C3-C4~Alkylengruppe bedeutet, die eine oder zwei nicht kumulierte Doppelbindungen enthalten kann und in der eine CH- oder CH2-Gruppe durch ein Stickstoff- oder Schwefelatom oder eine NH- oder N-CH3-Gruppe ersetzt sein kann und wobei der Ring entweder durch ein Fluor- oder Chlor- atom oder eine Methyl-, Methoxy-, Nitro- oder Aminogruppe monosubstituiert oder im Fall eines Benzolrings dieser durch Fluor- oder Chloratome oder Methyl-, Trifluormethyl-, Nitro-, Hydroxy-, Methoxy-, Amino-, Monomethyl- oder Dimethylamino- gruppen mono-, di- oder trisubstituiert sein kann,
und worin der X, Y und Z enthaltende Ring am Stickstoffatom Nr. 1 eine Cχ-C4-Alkyl-, Allyl- oder Benzylgruppe tragen und 1 bis 3 nicht kumulierte Doppelbindungen enthalten kann,
und deren Salze mit physiologisch verträglichen Säuren zur Herstellung von Arzneimitteln zur Sucht-Bekämpfung, zur Behandlung von Konzentrationsstörungen (attention deficit disorders) , Hyperaktivität bei Kindern (attention deficit hyperactivity disorders), Lern- und Gedächtnisschwäche (impaired cognitive function) .
Die erfindungsgemäße Verwendung betrifft alle Suchterkrankungen, seien sie durch Abusus von Substanzen verursacht oder andere Suchterkrankungen wie beispielsweise die Spielsucht. Suchterzeugende Substanzen können sein:
Opioide wie beispielsweise Morphin oder Heroin, Nikotin, Alkohol,
Substanzen, die mit dem Benzodiazepin-Rezeptor-Komplex inter- agieren, Sedativa oder Tranquilizer, wie beispielsweise die Benzodiazepine .
Als suchterzeugende Substanzen kommen erfindungsgemäß insbesondere Cocain oder Amphetamin sowie amphetaminartige Substanzen in Betracht.
Die Verbindungen der Formel I können sowohl in Form ihrer Racemate als auch ihrer optischen Isomeren verwendet werden.
Die Verbindungen können für die neue Indikation in üblicher Weise oral oder parenteral, intravenös oder intramuskulär verabfolgt werden.
Die Dosierung hängt vom Alter, Zustand und Gewicht des Patienten sowie von der Applikationsart ab. In der Regel beträgt die tägliche Wirkstoffdosis zwischen etwa 1 und 100 mg/kg Körpergewicht bei oraler Gabe und zwischen 0,1 und 10 mg/kg Körpergewicht bei parenteraler Gabe. Die Verbindungen können in gebräuchlichen galenischen Applikationsformen fest oder flüssig angewendet werden, z.B. als Tabletten, Filmtabletten, Kapseln, Pulver, Granulate, Dragees, Supposi- torien, Lösungen, Salben, Cremes oder Sprays. Diese werden in 5 üblicher Weise hergestellt. Die Wirkstoffe können dabei mit den üblichen galenischen Hilfsmitteln wie Tablettenbindern, Füllstoffen, Konservierungsmitteln, Tablettensprengmitteln, Fließreguliermitteln, Weichmachern, Netzmitteln, Dispergiermitteln, Emulgatoren, Lösungsmitteln, Retardierungsmitteln, Antioxidantien 10 und/oder Treibgasen verarbeitet werden (vgl. H. Sucker et al :
Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1978) . Die so erhaltenen Applikationsformen enthalten den Wirkstoff normalerweise in einer Menge von 1 bis 99 Gew.-%.
15 Folgende Substanzen seien als Beispiele für Verbindungen der Formel I genannt :
1. 1- (4-Fluor-phenyl) -4- [exo-6-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl]butan-l-on 20
2. l-Phenyl-4- [exo-6-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] - butan-1-on
3. 1- (4-Fluor-phenyl) -4- [exo-6 , 7-diphenyl-3-azabicyclo- 25 [3.2.0] -heptan-3-yl] -butan-1-on
4. 1- (4-Fluor-phenyl) -4- [exo-6-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl] -butan
30 5. l-Phenyl-2- [exo-6-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethan-1-on
6. 1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-3-azabicyclo-
[3.2.0]heptan-3-yl] -butan 35
7. 1- (4-Fluor-phenyl) -4- [exo-6-m-fluor-phenyl-3-azabicyclo-
[3.2.0]heptan-3-yl] -butan-1-on
8. 1- (4-Fluor-phenyl) -4- [exo-6-o-fluor-phenyl-3-azabicyclo- 40 [3.2.0]heptan-3-yl] -butan-1-on
9. 1- (4-Fluor-phenyl) -4- [exo-6-p-chlor-phenyl-3-azabicyclo- [3.2.0]heptan-3-yl] -butan-1-on
45 10. 1- (4-Fluor-phenyl) -4- [exo-6-m-chlor-phenyl-3-azabicyclo- [3.2.0]heptan-3-yl] -butan-1-on 11. 1- (4-Fluor-phenyl) -4- [exo-6-p-methoxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -butan-1-on
12. 1- (4-Fluor-phenyl) -4- [exo-6-m,p-dichlor-phenyl-3-aza- 5 bicyclo [3.2.0]heptan-3-yl] -butan-1-on
13. 1- (4-Fluor-phenyl) -4- [exo-6-m,p-dimethoxy-phenyl-3-aza- bicyclo [3.2.0]heptan-3-yl] -bu an-1-on
10 14. 1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-3-azabicy- clo- [3.2.0]heptan-3-yl] -butan-1-on
15. l-Phenyl-4- [exo-6-p-fluor-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl] -butan-1-on 15
16. 1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-3-azabicyclo-
[3.2.0]heptan-3-yl] -butan
17. 1- (4-Fluor-phenyl) -4- [exo-6-p-nitro-phenyl-3-azabicyclo- 20 [3.2.0]heptan-3-yl]-butan-l-on
18. 1- (4-Fluor-phenyl) -4- [exo-6-m-nitro-phenyl-3-azabicyclo-
[3.2.0]heptan-3-yl]-butan-l-on
25 19. 1- (4-Fluor-phenyl)-4- [exo-6-p-trifluormethyl-phenyl-3- azabicyclo [3.2.0]heptan-3-yl] -butan-1-on
20. 1- (4-Fluor-phenyl) -4- [exo-6-p-cyano-phenyl-3-azabicyclo-
[3.2.0]heptan-3-yl] -butan-1-on 30
21. 1- (4-Fluor-phenyl) -4- [exo-6-thien-3-yl-3-azabicyclo-
[3 .2 . 0 ] heptan-3-yl ] -butan-l-on
22 . 1- (4-Fluor-phenyl ) -4- [exo-6-pyrid-3-yl-3-azabicyclo- 35 [3 .2 . 0 ] heptan-3-yl] -butan-l-on
23. 1- (4-Fluor-phenyl) -3- [exo-6-p-fluor-phenyl-3-azabicyclo-
[3.2.0]heptan-3-yl]-propan-l-on
40 24. 1- (Bis-4-fluor-phenyl) -4- [exo-6-p-fluor-phenyl-3-azabicyclo- [3.2.0]heptan-3-yl] -butan
25. 1- (Bis-4-fluor-phenyl) -4- [exo-6-phenyl-3-azabicyclo- [3.2.0]heptan-3-yl]butan 45 26. 1- (4-Fluor-phenyl) -4- [exo-6-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl] -butan-1-ol
27. 1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-3-azabicyclo- 5 [3.2.0]heptan-3-yl] -butan-l-ol
28. 1- (4-Fluor-phenyl) -4- [exo-6, 7-diphenyl-3-azabicyclo- [3.2.0] heptan-3-yl] -butan-1-ol
10 29. l-Phenyl-4- [exo-6-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - butan-l-ol
30. l-Phenyl-4- [exo-6-p-fluor-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl] -butan-1-ol 15
31. 1- (4-Fluor-phenyl) -4- [exo-6-o-fluor-phenyl-3 -azabicyclo- [3.2.0]heptan-3-yl] -butan-1-ol
32. 1- (4-Fluor-phenyl)-4- [exo-6-m-chlor-phenyl-3-azabicyclo- 20 [3.2.0]heptan-3-yl]-butan-l-ol
33. 1- ( 4-Fluor-phenyl) -4- [exo-6-p-trifluormethyl-phenyl-3- azabicyclo [3.2.0]heptan-3-yl] -butan-l-ol
25 34. 1- (4-Fluor-phenyl) -4- [exo-6-p~amino-phenyl-3-azabicyclo- [3.2.0] -heptan-3-yl] -butan-1-on
35. N- (3- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -propyl) -
4-fluor-benzamid 30
36. N- (3- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - propyl ) -benzamid
37. N- (2-[exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - 35 ethyl) -4-fluor-benzamid
38. N- (2- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl ) -benzamid
40 39. N-(2-[exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl]- ethyl) -N-methyl-4-fluorbenzamid
40. N- (2- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl) -N-methyl-benzamid 45 41. N- (2- [exo-6~Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl) -N-methyl-4-isopropylbenzamid
42. N- (3-[exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - 5 propyl) -4-chlor-benzamid
43. N- (2- [exo-6-p-Trifluormethyl-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl] -ethyl) -4-chlor-benzamid
10 44. N- (3-[exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - propyl) -3-methoxy-benzamid
45. N- (3- [exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - propyl ) -3-nitro-benzamid 15
46. N- (3- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -propyl) -4-fluor-benzamid
47. N- (3- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 20 3-yl] -propyl) -benzamid
48. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl) -4-fluor-benzamid
25 49. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo[3.2.0]heptan- 3-yl] -ethyl) -benzamid
50. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl ] -ethyl ) -N-methyl-4-fluor-benzamid 30
51. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl) -N-methyl-benzamid
52. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 35 3-yl] -ethyl) -N-methyl-4-isopropylbenzamid
53. N- (3- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -propyl )-4-chlor-benzamid
40 54. N- (3- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -propyl) -3-methoxy-benzamid
55. N- (3- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -propyl) -3-nitro-benzamid 45 56. N- (2- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl) -4-chlor-benzamid
57. N- (2- [exo-6-o-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 5 3-yl] -ethyl) -4-chlor-benzamid
58. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl) -2-hydroxy-benzamid
10 59. N- (2- [exo-6-m-Hydroxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl) -4-chlor-benzamid
60. exo-3-n-Butyl-6-phenyl-3-azabicyclp [3.2.0]heptan
15 61. exo-3-Methyl-6-phenyl-3-azabicyclo [3.2.0]heptan
62. exo-3-Methyl-6-p-fluor-phenyl-3-azabicyclo [3.2.0]heptan
63. exo-3-n-Propyl-6-p-fluor-phenyl-3-azabicyclo [3.2.0]- 20 heptan
64. exo-3-Methyl-6, 7-diphenyl-3-azabicyclo [3.2.0] heptan
65. exo-3-n-Propyl-6-m-hydroxy-phenyl-3-azabicyclo [3.2.0]- 25 heptan
66. exo-3-Allyl-6-m-methoxy-phenyl-3-azabicyclo [3.2.0]- heptan
30 67. exo-3- (3 , 4-Dimethoxy) -phenethyl-6-phenyl-3-azabicyclo- [3.2.0] heptan
68. exo-3- (3 , 4-Dimethoxy) -phenethyl-6-p-fluor-phenyl-3- azabicyclo [3.2.0] -heptan 35
69. exo-3- (3 , 4-Dihydroxy) -phenethyl-3-azabicyclo [3.2.0]- heptan
70. exo-3-Phenethyl-6-p-fluor-phenyl-3-azabicyclo [3.2.0]- 40 heptan
71. 6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
45 72. (+)-6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on 73. (-) -6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
74. 6-ß- [exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] -ethyl-7- 5 methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
75. 6-ß- [exo-6 , 7-Diphenyl-3-azabicyclo [3.2.0]heptan-3-yl] -ethyl- 7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
10 76. 6-ß- [exo-6 , 7-bis- (p-Fluor-phenyl) -3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
77. 6-ß- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on 15
78. 6-ß- [exo-6-m-Methoxy-phenyl-3-azabicyclo [3.2.0] -heptan-3-yl] - ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
79. 6-ß- [exo-6-m-Hydroxy-phenyl-3-azabicyclo [3.2.0]heptan- 20 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
80. 6-ß- (2- [exo-6-p-Amino-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
25 81. 6-ß- [exo-6-p-Chlor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
82. 6-ß- [exo-6-p-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on 30
83. 6-ß- [exo-6-p-Nitro-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
84. 6-ß- [exo-6-m-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 35 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
85. 6-ß- [exo-6-p-Hydroxy-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
40 86. 6-ß- [exo-6-p-Trifluormethyl-phenyl-3-azabicyclo [3.2.0] - heptan-3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin- 5-on
87. 6-ß- [exo-6- (p-t-Butyl-phenyl) -3-azabicyclo [3.2.0]heptan- 45 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on 88. 6-ß- [endo-6- (p-t-Butyl-phenyl) -3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
89. 6-ß- [exo-6- (3, 4-Dichlor-phenyl)-3-azabicyclo [3.2.0]heptan- 5 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
90. 6-ß- [exo-6- (3, 4-Dimethoxy-phenyl) -3-azabicyclo [3.2.0]- heptan-3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin- 5-on 10
91. 6-ß- [exo-6-p-Cyano-penyl-3-azabicyclo [3.2.0] heptan- 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
92. 6-ß- [exo-6-(3, 4-Dihydroxy-phenyl ) -3-azabicyclo [3.2.0]- 15 heptan-3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-
5-on
93. 6-ß- [exo-6- (o-Fluor-phenyl-) -3-azabicyclo [3.2.0] heptan-
3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on 20
94. 6-ß- [exo-6-Thien-3-yl-3-azabicyclo[3.2.0]heptan-3-yl] - ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
95. 6-ß- [exo-6-(5-Chlor-thien-2-yl)-3-azabicyclo[3.2.0]heptan- 25 3-yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
96. 6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-7-methyl-2 , 3-dihydro-5H-thiazolo [3 , 2-a]pyrimidin- 5-on 30
97. 6-ß- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-7-methyl-2 , 3-dihydro-5H-thiazolo [3 , 2-a]pyrimidin- 5-on
35 98. 6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - ethyl-2 , 3 , 7-trimethyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
99. 6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on 40
100.6-ß- [exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] -ethyl-5H- thiazolo [3 , 2-a]pyrimidin-5-on
101.7-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 45 ethyl-8-methyl-2H, 6H-pyrimido [2, 1-b] [1, 3] thiazin-6-on 102.7-ß- [exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] -ethyl-
8-methyl-2H, 6H-pyrimido [2 , 1-b] [1,3] thiazin-6-on
103.7-ß- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 5 ethyl-8-methyl-2H, 6H-pyrimido [2, 1-b] [1, 3 ] thiazin-6-on
104.7-ß- [exo-6-p-Chlor-phenyl-3-azabicyclo [3.2.0]he tan-3-yl] - ethyl-8-methyl-2H, 6H-pyrimido [2, 1-b] [1,3] thiazin-6-on
10 105.7-ß- [exo-6-p-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-8-methyl-2H, 6H-pyrimido [2, 1-b] [1.3] thiazin-6-on
106.7-ß- [exo-6-m-Hydroxy-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl]-ethyl-8-methyl-2H, 6H-pyrimido [2 , 1-b] [1,3] thiazin-6-on 15
107.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion
108. (+) -3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 20 3-yl] -ethyl-2, 4-(lH, 3H) -chinazolindion
109. (-) -3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-2, 4-(lH, 3H) -chinazolindion
25 110.3-ß- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -ethyl-2 , - (1H, 3H) -chinazolindion
111.3-ß- [exo-6-m-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion 30
112.3-ß- [exo-6-p-Cyano-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion
113.3-ß- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl-2, 4-(lH, 3H) -chinazolindion
114.3-ß- [exo-6-p-Hydroxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion
40 115.3-ß- [exo-6-p-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion
116.3-ß- [exo-6-m-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion 45 117.3-ß- [exo-6-p-Nitro-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2 , 4- (1H, 3H) -chinazolindion
118.3-ß- [endo-6-p-Nitro-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 5 ethyl-2, 4-(lH, 3H) -chinazolindion
119.3-ß- [exo-6-m-Hydroxy-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] - ethyl-2 , 4- (1H, 3H) -chinazolindion
10 120.3-ß- [exo-6-p-Amino-phenyl-3-azabicyclo [3.2.0]heptan-3-yl) - ethyl-2 , 4- (1H, 3H) -chinazolindion
121.3-ß- [exo-6-p-Jod-phenyl-3-azabicyclo [3.2.0]heptan-3-yl ) - ethyl-2 , 4- (1H, 3H) -chinazolindion 15
122.3-ß- [exo-6-p-Trifluormethyl-phenyl-3-azabicyclo [3.2.0]- heptan-3-yl] -ethyl-2 , 4- ( 1H, 3H) -chinazolindion
123.3-ß- [exo-6- (3 , 4-Dichlor-phenyl ) -3-azabicyclo [3.2.0]- 20 heptan-3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
124.3-ß- [exo-6- (3 , 4-Dihydroxy-phenyl) -3-azabicyclo [3.2.0]- heptan-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion
25 125.3-ß- [exo-6-(3, 5-Dichlor-phenyl ) -3-azabicyclo [3.2.0]heptan- 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
126.3-ß- [exo-6-o-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yi] - ethyl-2 , 4- ( 1H, 3H) -chinazolindion 30
127.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-8-methyl-2 , 4- ( 1H, 3H) -chinazolindion
128.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl-7-chlor-2, - (1H, 3H) -chinazolindion
129.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - ethyl-7-fluor-2 , 4- (1H, 3H) -chinazolindion
40 130.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-5-chlor-2, 4- (1H, 3H) -chinazolindion
131.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6-fluor-2, 4- (1H, 3H) -chinazolindion 45 132.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6-methyl-2 , 4- ( 1H, 3H) -chinazolindion
133.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 5 ethyl-8-methoxy-2 , 4- (1H, 3H) -chinazolindion
134.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6-trifluormethyl-2 , 4- (1H, 3H) -chinazolindion
10 135.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-7-nitro-2, 4- (1H, 3H) -chinazolindion
136.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6-nitro-2, 4- (1H, 3H) -chinazolindion 15
137.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-7-amino-2, 4- (1H, 3H) -chinazolindion
138.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 20 ethyl-6-amino-2 , 4- (1H, 3H) -chinazolindion
139.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6-hydroxy-2 , 4- (1H, 3H) -chinazolindion
25 140.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-5-chlor-2, 4- (1H, 3H) -chinazolindion
141.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6, 7-dimethoxy-2 , 4- (1H, 3H) -chinazolindion 30
142.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6, 8-dichlor-2 , 4- (1H, 3H) -chinazolindion
143.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl-6, 7, 8-trimethoxy-2 , 4- (1H, 3H) -chinazolindion
144.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-l-methyl-2 , 4- (1H, 3H) -chinazolindion
40 145.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-l-ethyl-2, 4- (1H, 3H) -chinazolindion
146.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-l-allyl-2, 4- (1H, 3H) -chinazolindion 45 147.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] - ethyl-l-benzyl-2 , 4- (1H, 3H) -chinazolindion
148.3-γ- [exo-6-p-Fluor-pheny1-3-azabicyclo [3.2.0]heptan-3-yl] - 5 propyl-2 , 4- (1H, 3H) -chinazolindion
149.3-δ- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - butyl-2, 4- (1H, 3H) -chinazolindion
10 150.3-ß-[exo-6-(2-Thienyl)-3-azabicyclo[3.2.0]heptan-3-yl]- ethyl-2, 4- (1H, 3H) -chinazolindion
151.3-ß- [exo-6-(5-Chlor-2-thienyl)-3-azabicyclo[3.2.0]heptan- 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion 15
152.3-ß- [exo-6- ( 3-Thienyl ) -3 -azabicyclo [3.2.0] heptan-3-yl] - ethyl-2 , 4- (1H, 3K) -chinazolindion
153.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 20 ethyl-lH-thieno [3 , 2-d]pyrimidin-2 , 4-dion
154.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-lH-thieno [2 , 3-d]pyrimidin-2 , 4-dion
25 155.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] - ethyl-lH-thieno [3 , 4-d]pyrimidin-2 , 4-dion
156.3-ß- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0] heptan-3-yl] - ethyl-1-methyl-lH, 3H-pyrido [2 , 3-d] pyrimidin-2 , 4-dion 30
157.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methyl-3H-chinazolin-4-on
158.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl-2-methoxy-3H-chinazolin-4-on
159.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methyl-4H-pyrido [1, 2-a]pyrimidin-4-on Dihydrochlorid
40 160.3-ß- [exo-6-Phenyl-3-azabicyclo[3.2.0]heptan-3-yl] -ethyl- 2-methyl-4H-pyrido [1, 2-a]pyrimidin-4-on
161.3-ß- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methyl-4H-pyrido [1 , 2-a]pyrimidin-4-on 45 162.3-ß- [exo-6-m-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2-methyl-4H-pyrido [1, 2-a]pyrimidin-4-on
163.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
5 3-yl] -ethyl-2, 6-dimethyl-4H-pyrido [1, 2-a]pyrimidin-4-on
164.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2 , 7-dimethyl-4H-pyrido [1, 2-a]pyrimidin-4-on
10 165.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2 , 8-dimethyl-4H-pyrido [1 , 2-a]pyrimidin-4-on
166.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2 , 9-dimethyl-4H-pyrido [1 , 2-a]pyrimidin-4-on 15
167.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2 , 6, 8-trimethyl-4H-pyrido [1, 2-a]pyrimidin-4-on
168.3-ß- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan- 20 3-yl] -ethyl-2, 7-dimethyl-4H-pyrido [1, 2-a]pyrimidin-4-on
169.3-ß- [exo-6-o-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2, 7-dimethyl-4H-pyrido [1, 2-a]pyrimidin-4-on
25 170.3-ß- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -ethyl- 2 , 8-dimethyl-4H-pyrido [1, 2-a]pyrimidin-4-on
171.3-ß- [exo-6-m-Chlor-pheny1-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2 , 9-dimethyl-4H-pyrido [1 , 2-a]pyrimidin-4-on 30
172.3-ß- [exo-6-(5-Chlor-thien-2-yl)-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2-methyl-4H-pyrido [1, 2-a]pyrimidin-4-on
173.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl-6, 7,8, 9-tetrahydro-2-methyl-4H-pyrido [1, 2-a]pyrimidin-
4-on
174.3-ß- [exo-6-p-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6, 7,8, 9-tetrahydro-2-methyl-4H-pyrido [1, 2-a]pyrimidin- 40 4-on
175.3-ß- [exo-6-p-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-6, 7, 8, 9-tetrahydro-2-methyl-4H-pyrido [1, 2-a]pyrimidin- 4-on 45 176.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methyl-4H-pyrimido [1 , 2-a]pyrimidin-4-on
177.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 5 ethyl-2-methyl-7-chlor-4H-pyrimido [1, 2-a]pyrimidin-4-on
178.6-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-7-methyl-1H, 5H-imidazo [1, 2-a]pyrimidin-5-on
10 179.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methyl-7 , 8-dihydro-4H, 6H-pyrrolo [1 , 2-a]pyrimidin- 4-on
180.2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]hept n-3-yl] - 15 methyl-benzimidazol
181.1-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-benzimidazol
20 182.1-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2, 3-dihydro-benzimidazol-2-on
183.2- [exo-6-m-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - methyl-benzimidazol 25
184.3-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-indol, Schmp. 193-195°C (Hydrochlorid)
185.3-ß- (2- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.2.0]heptan- 30 3-yl] -ethyl-indol
186.3-ß- [exo-6-Pheny1-3-azabicyclo [3.2.0]heptan-3-yl] -ethyl- indol, Schmp. 104-105°C (Hydrochlorid)
35 187.3-ß- [exo-6-m-Methoxy-phenyl-3-azabicyclo [3.2.0] eptan-3-yl] - ethyl-indol
188.2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - methyl-3 , 4-dihydro-chinazolin-4-on 40
189.2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - methyl-3 , 4-dihydro-chinazolin-4-thion
190.2- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -methyl- 45 3 , 4-dihydro-chinazolin-4-on 191.2- [exo-6-m-Chlor-pheny1-3-azabicyclo [3.2.0]heptan-3-yl] - methyl-3 , 4-dihydro-chinazolin-4-on
192.2- [exo-6-o-Methoxy-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 5 methyl-3 , 4-dihydro-chinazolin-4-on
193.2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - methy1-4-hydroxy-6-methyl-pyrimidin
10 194.6- [exo-6-p-Fluor-pheny1-3-azabicyclo [3.2.0]heptan-3-yl] - methy1-2-methy1-4-hydroxy-pyrimidin
195.6- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - methyl-uracil 15
196.6- [exo-6-Phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -methyl- uracil
197.6- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 20 1,2,3, 4-tetrahydro-1 , 3-dimethyl-2 , 4-dioxo-pyrimidin
198.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl]-ethyl-l, 2,3, 4-tetrahydro-6-methyl-2 , 4-dioxo-pyrimidin
25 199.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-1 , 2,3, 4-tetrahydro-l , 6-dimethyl-2 , 4-dioxo-pyrimidin
200.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-1 , 2,3, 4-tetrahydro-3 , 6-dimethyl-2 , 4-dioxo-pyrimidin 30
201.5-ß- [exo-6-p-Fluor-pheny1-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-1 , 2,3, 4-tetrahydro-3 , 6-dimethyl-2 , 4-dithio-pyrimidin
202.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl-1 , 2,3, 4-tetrahydro-l , 3 , 6-trimethyl-2 , 4-dioxo-pyrimidin
203.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-1, 2,3, 4-tetrahydro-6-amino-l-methyl-2 , 4-dioxo- pyrimidin 40
204.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-amino-6-methyl-4 (3H) -pyrimidinon
205.5-ß- [exo-6-p-Fluor-pheny1-3-azabicyclo [3.2.0]heptan-3-yl] - 45 ethyl-2-amino-3 , 6-dimethyl-4 (3H) -pyrimidinon 206.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
207.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - 5 ethyl-2-methylamino-3-ethyl-6-methyl-4 (3H) -pyrimidinon
208.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-amino-3-ethyl-6-methyl-4 (3H) -pyrimidinon
10 209.5-ß- [exo-6-p-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
210.5-ß- [exo-6-m-Chlor-pheny1-3-azabicyclo [3.2.0] heptan-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
15
211.5-ß- [exo-6-o-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
212.5-ß- [exo-6-p-Trifluormethyl-phenyl-3-azabicyclo [3.2.0]- 20 heptan-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H)- pyrimidinon
213.5-ß- [exo-6-p-Cyano-phenyl-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon 25
214.5-ß- [exo-6-m-Fluor-pheny1-3-azabicyclo [3.2.0]heptan-
3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
215.5-ß- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan- 30 3-yl] -ethyl-2-methylamino-4-methoxy-6-methyl-pyrimidin
216.3-ß- [exo-6-Phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion
217.3-ß- [endo-6-Phenyl-7-methyl-l, 5-cis-3 , 7-diazabicyclo [3.3.0]- 35 octan-3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
218.3-ß- [exo-6-p-Fluor-phenyl-7-methyl-1, 5-cis-3, 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
40 219.3-ß-[exo-6-p-Trifluormethyl-phenyl-7-methyl-l, 5-cis-3,7- diazabicyclo [3.3.0] octan-3-yl] -ethyl-6-fluor-2 , 4- ( 1H, 3H) - chinazolindion
220.3-ß- [exo-6-m-Chlor-phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- 45 cyclo[3.3.0] octan-3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion 221.3-ß- [exo-6-p-Methoxy-phenyl-7 -methyl-1, 5-cis-3 , 7-diazabi- cyclo[3.3.0]octan-3-yl] -ethyl-6-methyl-2 , 4- (1H,3H) -chinazolindion
5 222.5-ß- [exo-6-Phenyl-7-methyl-1, 5-cis-3 , 7-diazabicyclo [3.3.0] oc- tan-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
223.5-ß- [exo-6-p-Fluor-phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl ] -ethyl-2-methylamino-3 , 6-dimethyl- 10 4 (3H) -pyrimidinon
224.1-ß- [exo-6-p-Fluor-phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl-2 (3H) -benzimidazolon
15 225.5-ß- [exo-6-p-Nitro-phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl- 4 (3H) -pyrimidinon
226.5-ß- [exo-6-Phenyl-7-methyl-l, 5-cis-3 , 7-diazabicyclo- 20 [3.3.0] -octan-3-yl]-ethyl-2-methylamino-3, 6-dimethyl-4 (3H)- pyrimidinon
227.5-ß- [endo-6-Phenyl-7-methyl-l, 5-cis-3 , 7-diazabicyclo-
[3.3.0] -octan-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) - 25 pyrimidinon
228.3-ß- [exo-6-p-Fluor-phenyl-7 -methyl-1, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl-2-methyl-4H-pyrido [1.2-a] - pyrimidin-4-on 30
229.1-ß- [exo-6-p-Fluor-phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl-indolin-2-on
230.6-ß- [exo-δ-p-Fluor-phenyl-7-methyl-l, 5-cis-3 , 7-diazabicyclo- 35 [3.3.0]octan-3-yl] -ethyl-7-methyl-5H-thiazolo [3.2-a] - pyrimidin-5-on
231.1-ß- [exo-6-p-Fluor-phenyl-7-methyl-1, 5-eis-3 , 7-diazabicyclo- [3.3.0] octan-3-yl] -ethyl-2 (1H) -chinolon 40
232.3-ß- [7-Phenyl-l, 5-cis-3 , 7-diazabicyclo [3.3.0] octan-3-yl] - ethyl-2 , 4- (1H, 3H) -chinazolindion
233.3-ß- [7-p-Fluor-phenyl-l, 5-cis-3 , 7-diazabicyclo [3.3.0] oetan- 45 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion 234.5-ß- 7-p-Fluor-phenyl-l , 5-cis-3 , 7-diazabicyclo [3.3.0] octan- 3-yl -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
235.3-ß- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.1.0]hexan-3-yl] - 5 ethyl 2, 4- (1H, 3H) -chinazolindion
236.3-ß- exo-6-Phenyl-3-azabicyclo [3.1.0]hexan-3-yl] -ethyl- 2,4- 1H, 3H) -chinazolindion
10 237.3-ß- 6, 6-Diphenyl-3 -azabicyclo [3.1.0]hexan-3-yl] -ethyl- 2,4- 1H, 3H) -chinazolindion
238.5-ß- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.1.0]hexan-3-yl] - ethyl 2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
15
239.6-ß exo-6-m-Chlor-phenyl-3 -azabicyclo [3.1.0]hexan-3-yl] - ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
240.3-ß- 6-p-Fluor-phenyl-l , 5-cis-3 -azabicyclo [3.3.0] oct-6-en- 20 3-yl -ethyl-2 , 4- (1H, 3H) -chinazolindion
241.5-ß- 6-p-Fluor-phenyl-l , 5-cis-3 -azabicyclo [3.3.0] oct-6-en- 3-yl -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
25 242.6-ß- 6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [3.3.0] oct-6-en- 3-yl -ethyl-7-methyl-5H-thiazolo [3 , 2-a]pyrimidin-5-on
243.1-ß- 6-Phenyl-1, 5-eis-3 -azabicyclo [3.3.0] oct-6-en-3-yl] - ethyl-2 (3H) -benzimidazolon 30
244.1-ß- 6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [3.3.0] oct-6-en- 3-yl -ethyl-indolin-2-on
245.1-ß- 6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [3.3.0] oct-6-en- 35 3-yl -ethyl-2 (1H) -chinolon
246.3-ß- exo-6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [3.3.0] oetan- 3-yl -ethyl-2, 4- (1H, 3H) -chinazolindion
40 247.5-ß- exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [3.3.0] oetan- 3-yl -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
248.6-ß- [exo-6-Phenyl-l, 5-cis-3 -azabicyclo [3.3.0] octan-3-yi ethyl-7-methyl-5H-thiazolo [3.2-a]pyrimidin-5-on
45 249. ι-ß-[exo-6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [3.3.0] octan-
3-yl] -ethyl-indolin-2-on
250. ι-ß-[exo-6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [3.3.0] octan-
5 3-yl] -ethyl-2 ( 1H) -chinolon
251. 3-ß-[endo-6-p-Fluor-phenyl-1, 5-eis-3-azabicyclo [3.3.0] octan- 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
10 252. 5-ß-[endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [3.3.0] oetan-
3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
253 6-ß-[endo-Phenyl-1, 5-eis-3-azabicyclo [3.3.0] octan-3-yl] - ethyl 7-methyl-5H-thiazolo [3.2-a]pyrimidin-5-on
15
254 ι-ß-[endo-6-p-Fluor-phenyl-l, 5-cis-3 -azabicyclo [3.3.0] oetan-
3-yl] -ethyl-indolin-2-on
255 ι-ß-[endo-6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [3.3.0] oetan-
20 3-yl] -ethyl-2 ( 1H) -chinolon
256 3-ß-[exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [3.3.0] oetan-
3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion
25 257 5-ß-[exo-7-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [3.3.0] oetan-
3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
258.6-ß exo-7-Phenyl-1 , 5-cis-3-azabicyclo [3.3.0] octan-3-yl] - ethyl-7-methyl-5H-thiazolo [3.2-a]pyrimidin-5-on
30
259. 1-ß- exo-7-p-Fluor-phenyl-i, 5-cis-3 -azabicyclo [3.3.0] oetan-
3-yl -ethyl-indolin-2-on
260.1-ß- exo-7-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [3.3.0] oetan- 35 3-yl -ethyl-2 (1H) -chinolon
261.3-ß- endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 3-yl -ethyl-2, 4- (1H, 3H) -chinazolindion
40 262 5-ß- endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-
3-yl -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
263.3-ß- [endo-6-Phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-3-yl] ethyl-2 , 4- (1H, 3H) -chinazolindion
45 264.5-ß- [endo-6-Phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
265.3-ß- [endo-6-p-Trifluormethyl-phenyl-1, 5-cis-3-azabicyclo- 5 [4.3.0]non-3-yl] -ethyl-2 , 4- ( 1H, 3H) -chinazolindion,
266.5-ß- [endo-6-p-Trifluormethyl-phenyl-1 , 5-cis-3-azabicyclo- [4.3.0]non-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) - pyrimidinon 10
267.3-ß- [endo-6-p-Fluor-phenyl-1, 5-cis-3-azabicyclo [4.3.0]non- 7-en-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion
268.5-ß- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 15 7-en-3-yl] -ethyl-2 -methylamino-3 , 6-dimethyl-4 (3H) - pyrimidinon
269.1-ß- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-
7-en-3-yl] -ethyl-2 (3H) -benzimidazolon 20
270.1-ß- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-
7-en-3-yl] -ethyl-indolin-2-on
271.3-ß- [6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-6-en- 25 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
272.5-ß- [6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-6-en- 3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
30 273.3-ß-[6-Phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-6-en-3-yl] - ethyl-2 , 4- (1H, 3H) -chinazolindion
274.5-ß- [6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0] non-6-en-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon 35
275.3-ß- [6-p-Trifluormethyl-phenyl-1, 5-cis-3-azabicyclo-
[4.3.0]non-6-en-3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
276.5-ß- [6-p-Trifluormethyl-phenyl-1, 5-cis-3-azabicyclo [4.3.0]- 40 non-6-en-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) - pyrimidinon
277.1-ß- [6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-6-en- 3-yl] -ethyl-2 (3H) -benzimidazolon 45 278.1-ß- [6-p-Fluor-phenyl-l, 5-eis-3-azabicyclo [4.3.0]non-6-en- 3-yl] -ethyl-indoiin-2-on
279.1-ß- [6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-6-en- 5 3-yl] -ethyl-2 (1H) -chinolon
280.3-ß- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-7- en-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolidon
10 281.5-ß- [exo-6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non-7- en-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
282.3-ß- [exo-6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non-7- en-3-yl] -ethyl-2 -methyl-4H-pyrido [1.2-a]pyrimidin-4-on 15
283.1-ß- [exo-6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [4.3.0] non-7- en-3-yl] -ethyl-2 (1H) -chinolon
284.1-ß- [exo-6-p-Fluor-phenyl-1 , 5-eis-3 -azabicyclo [4.3.0]non-7- 20 en-3-yl] -ethyl-2 (3H) -benzimidazolon
285.1-ß- [exo-6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [4.3.0] non-7- en-3-yl] -ethyl-indolin-2-on
25 286.3-ß-[exo-6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0]non-7-en-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion
287.5-ß- [exo-6-Phenyl-1, 5-cis-3 -azabicyclo [4.3.0]non-7-en-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon 30
288.3-ß- [exo-6-p-Fluor-phenyl-1, 5-eis-3-azabicyclo [4.3.0]non- 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
289.5-ß- [exo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 35 3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H)pyrimidinon
290.3 -ß-[exo-6-Phenyl-l,5-cis-3 -azabicyclo [4.3.0]non-3-yl] -ethyl- 2 , 4- (1H, 3H) -chinazolindion
40 291.5-ß- [exo-6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0] non-3-yl] -ethyl- 2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
292.6-ß- [exo-6-p-Fluor-phenyl-1, 5-cis-3 -azabicyclo [4.3.0]non- 3-yl] -ethy1-7-methyl-5H-thiazolo [3.2-a] -pyrimidin-5-on 45 293.1-ß- [exo-6-p-Fluor-phenyl-l , 5-cis-3 -azabicyclo [4.3.0] non- 3-yl] -ethyl-2 (3H) -benzimidazolon
294.1-ß- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non- 5 3-yl] -ethyl-indolin-2-on
295.1-ß- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0] non- 3-yl] -ethyl-2 (1H) -chinolon
10 296.3 -ß-[exo-7-Phenyl-l,5-cis-3-azabicyclo [4.3.0] non-8-en-3-yl] - ethyl-2 , 4- (1H, 3H) -chinazolindion
297.5-ß- [exo-7-Phenyl-l, 5-cis-3-azabicyclo [4.3.0] non-8-en-3-yl] - ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon 15
298.3-ß- [exo-7-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-
8-en-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion
299.5-ß- [exo-7-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0] non- 20 8-en-3-yl] -ethyl-2 -methylamino-3 , 6-dimethyl-4 (3H) - pyrimidinon
300.3-ß- [7-p-Fluor-phenyl-3 -azabicyclo [4.3.0]non-l-en-3-yl] - ethyl-2, 4- (1H, 3H) -chinazolindion 25
301.5-ß- [7-Phenyl-3-azabicyclo[4.3.0] non-l-en-3-yl] -ethyl- 2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
302.5-ß- [7-p-Fluor-phenyl-3 -azabicyclo [4.3.0]non-l-en-3-yl] - 30 ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
303.3-ß- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non- 3-yl] -ethyl-2, 4- (1H, 3H) -chinazolindion
35 304.5-ß- [exo-7-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) -pyrimidinon
305.1-ß- [exo-7-p-Fluor-phenyl-1, 5-eis-3-azabicyclo [4.3.0]non- 3-yl] -ethyl-2 (3H) -benzimidazolon 40
306.1-ß- [exo-7-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-
3-yl] -ethyl-indolin-2-on
307.1-ß- [exo-7-p-Fluor-phenyl-l , 5-cis-3 -azabicyclo [4.3.0] on- 45 3-yl] -ethyl-2 (1H) -chinolon 308.3-ß- [6-p-Fluor-phenyl-l , 5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0]- occ-6-en-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion
309.5-ß- [6-p-Fluor-phenyl-l, 5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0]- 5 oct-6-en-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl-4 (3H) - pyrimidinon
310.3-ß- [exo/endo-6-p-Fluor-phenyl-l, 5~cis-8-oxa-3 , 7-diazabi- cyclo[3.3.0] -octan-3-yl] -ethyl-2 , 4- (1H, 3H) -chinazolindion 10
311.5-ß- [exo/endo-6-p-Fluor-phenyl-l, 5-cis-8-oxa-3 , 7-diazabi- cyclo [3.3.0] -octan-3-yl] -ethyl-2-methylamino-3 , 6-dimethyl- 4 (3H) -pyrimidinon
15 312.1-ß- [6-p-Fluor-phenyl-l, 5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0]- oct-6-en-3-yl] -ethyl-indolin-2-on
313.6-ß-[6-Phenyl-l, 5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0] - oct-6-en-3 -yl] -ethyl-7-methyl-5H-thiazolo [3 , 2-a] pyrimidin- 20 5-on
314. N- (2-[exo-6-Phenyl-7-methyl-l, 5-cis-3, 7-diazabicyclo [3.3.0] octan-3-yl] -ethyl) -4-fluor-benzamid
25 315. N- (2- [endo-6-Phenyl-7-methyl-l, 5-cis-3 , 7-diazabicyclo [3.3.0]- octan-3-yl] -ethyl) -4-fluor-benzamid
316. N- (2- [exo-6-p-Fluor-phenyl-7-methyl-l, 5-cis-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl) -4-fluor-benzamid 30
317. N- (2- [exo-6-p-Trifluormethyl-phenyl-7-methyl-l, 5-cis-3 , 7- diazabicyclo [3.3.0] octan-3-yl] -ethyl) -benzamid
318. N- (2- [exo-6-m-Chlor-phenyl-7-methyl-l, 5-cis-3, 7-diazabi- 35 cyclo [3.3.0] octan-3-yl] -ethyl) -benzamid
319. N- (2- [exo-6-p-Methoxy-phenyl-7-methyl-l, 5-cis-3, 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl) -4-chlor-benzamid
40 320. N- (2- [exo-6-Phenyl-7-methyl-1, 5-cis-3, 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl) -naphthalin-1-carbonamid
321.1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-7-methyl-l, 5- cis-3 , 7-diazabicyclo [3.3.0] octan-3-yl] -butan-1-on 45 322.1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-7-methyl-1, 5- cis-3 , 7-diazabicyclo [3.3.0] octan-3-yl] -butan-l-ol
323. N- (2- [exo-6-p-Fluor-phenyl-l, 5-cis-3 -azabicyclo [4.3.0] 5 non-3-yl] -ethyl) -benzamid
324.1- (2-[exo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0] non-3-yl] -ethyl) -naphthalin
10 325.1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-1, 5-cis-3- azabicyclo [4.3.0]non-3-yl] -butan-1-on
326.1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-1, 5-cis-3- azabicyclo [4.3.0]non-3-yl] -butan-1-ol 15
327. N- (2- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-
3-yl] -ethyl) -2- (N-methyl ) -amino-benzamid
328. N- (2- [exo-6-p-Fluor-phenyl-1 , 5-eis-3 -azabicyclo [4.3.0]non- 20 3-yl] -ethyl) -5-chlor-thien-2-yl-carbonamid
329. N- (2- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-
3-yl] -ethyl) -inden-3-carbonamid
25 330. N- (2- [exo-6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0]non-3-yl] - ethyl) -4-fluor-benzamid
331. N- (2-[exo-6-Phenyl-l, 5-cis-3-azabicyclo [4.3.0]non-3-yl] - ethyl) -naphthalin-1-carbonamid 30
332.1- (2- [exo-6-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [4.3.0]non-
7-en-3-yl] -ethyl) -naphthalin
333.1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-1, 5-cis-3-aza- 35 bicyclo [4.3.0]non-7-en-3-yl] -butan-1-on
334. N- (2- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-
7-en-3-y1] -ethyl) -benzamid
40 335. N- (2- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non- 7-en-3-yl] -ethyl) -inden-3-carbonamid
336. N- (2- [exo-6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non- 7-en-3-yl] -ethyl) -naphthalin-1-carbonamid 45 337. N- (2- [exo-6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0]non-7-en-3-yl] - ethyl) -4-fluor-benzamid
338. N- (2- [exo-6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0] non-7-en-3-yl] - 5 ethyl) -3-chlor-l-benzothien-2-yl-carbonamid
339.1- (2- [6-p-Fluor-phenyl-l , 5-eis-3 -azabicyclo [4.3.0] non-6-en- 3-yl] -ethyl) -naphthalin
10 340.1- (4-Fluor-phenyl) -4- [6-p-fluor-phenyl-1 , 5-cis-3-azabicyclo- [4.3.0]non-6-en-3-yl] -butan-1-on
341.1- (4-Fluor-phenyl) -4- [ 6-p-fluor-phenyl-1, 5-cis-3-azabicyclo- [4.3.0]non-6-en-3-yl] -butan-l-ol 15
342. N- (2- [6-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non-6-en-
3-yl] -ethyl) -2- (N-methyl) -amino-benzamid
343. N- (2- [6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non-6-en- 20 3-yl] -ethyl) -5-chlor-thien-2-yl-carbonamid
344. N- (2- [6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non-6-en-
3-yl ] -ethyl ) -benzamid
25 345. N- (2- [6-Phenyl-l, 5-cis-3 -azabicyclo [4.3.0]non-6-en-3-yl] - ethyl) -3-chlor-l-benzothien-2-yl-carbonamid
346. N- (2- [6-p-Trifluormethyl-phenyl-1, 5-cis-3-azabicyclo [4.3.0]- non-6-en-3-yl] -ethyl) -naphthalin-1-carbonamid 30
347. N- (2- [6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0] non-6-en-
3-yl] -ethyl) -inden-3-carbonimid
348. N- (2- [6-p-Fluor-phenyl-1, 5-eis-3-azabicyclo [4.3.0]non-6-en- 35 3-yl] -ethyl) -napthalin-1-carbonamid
349.1- (2- [endo-6-p-Fluor-phenyl-1, 5-cis-3-azabicyclo [4.3.0]non- 3-yl] -ethyl) -naphthalin
40 350.1- (4-Fluor-phenyl) -4- [endo-6-p-Fluor-phenyl-l, 5-cis-3- azabicyclo [4.3.0]non-3-yl] -butan-1-on
351.1- (4-Fluor-phenyl) -4- [endo-6-p-Fluor-phenyl-l, 5-cis-3- azabicyclo [4.3.0]non-3-yl] -butan-l-ol 45 352. N- (2- [endo-6-p-Fluor-phenyl-1, 5-cis-3 -azabicyclo [4.3.0]non- 3-yl] -2- (N-methyl) -amino-benzamid
353. N- (2- [endo-6-p-Fluor-phenyl-1, 5-eis-3-azabicyclo [4.3.0]non- 5 3 -yl ] -ethyl ) -benzamid
354. N- (2- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 3-yl] -ethyl) -5-chlor-thien-2-yl-carbonamid
10 355. N- (2- [endo-6-Phenyl-1, 5-cis-3-azabicyclo [4.3.0]non-3-yl] - ethyl) -4-fluor-benzamid
356. N- (2- [endo-6-p-Trifluormethyl-phenyl-1, 5-cis-3-azabicyclo- [4.3.0]non-3-yl] -ethyl) -inden-3-carbonamid 15
357.2- (2- [endo-6-p-Fluor-phenyl-1, 5-cis-3-azabicyclo [4.3.0]non- 7-en-3-yl] -ethyl ) -naphthalin
358. N- (2- [endo-6-p-Fluor-phenyl-1, 5-cis-3-azabicyclo [4.3.0]non- 20 7-en-3-yl] -ethyl) -benzamid
359. N- (2- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 7-en-3-yl] -ethyl) -2- (N-methyl) amino-benzamid
25 360. N- (2- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [4.3.0]non- 7-en-3-yl] -ethyl) -naphthalin-1-carbonamid
361.1- (2- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0] non-
8-en-3-yl] -ethyl) -naphthalin 30
362.1- (4-Fluor-phenyl) -4- [exo-7-p-fluor-phenyl-1, 5-eis-3- azabicyclo [4.3.0]non-8-en-3-yl] -butan-1-on
363. N- (2- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0] non- 35 8-en-3-yl] -ethyl) -benzamid
364. N- (2- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non- 8-en-3-yl] -ethyl) -5-chlor-thien-2-yl-carbonamid
40 365. N- (2- [exo-7-p-Fluor-phenyl-l, 5-eis-3 -azabicyclo [4.3.0]non- 8-en-3-yl] -ethyl ) -3-chlor-l-benzothien-2-yl-carbonamid
366. N- (2- [exo-7-Phenyl-1, 5-cis-3-azabicyclo [4.3.0]non-8-en- 3-yl] -ethyl) -inden-3-carbonamid 45 367. N- (2- [exo-7-Phenyl-1, 5-cis-3 -azabicyclo [4.3.0] non-8-en- 3-yl] -ethyl) -naphthalin-1-carbonamid
368.1- (2- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [4.3.0]non- 5 3-yl] -ethyl) -naphthalin
369.1- (4-Fluor-phenyl) -4- [exo-7-p-fluor-phenyl-1, 5-eis-3- azabicyclo [4.3.0]non-3-yl] -butan-1-on
10 370.1- (4-Fluor-phenyl) -4- [exo-7-p-fluor-phenyl-1, 5-cis-3- azabicyclo [4.3.0]non-3-yl] -butan-l-ol
371. N- (2- [exo-7-p-Fluor-phenyl-1 , 5-eis-3 -azabicyclo [4.3.0]non- 3-yl ] -ethyl) -2 - (N-methyl ) -amino-benzamid 15
372. N- (2- [exo-7-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [4.3.0] non-
3-yl] -ethyl) -benzamid
373. N- (2- [exo-7-p-Fluor-phenyl-l , 5-eis-3 -azabicyclo [4.3.0] non- 20 3-yl] -ethyl) -5-chlor-thien-2-yl-carbonamid
374. N- (2- [exo-7-p-Fluor-phenyl-1, 5-cis-3 -azabicyclo [4.3.0]non- 3-yl] -ethyl) -naphthalin-1-carbonamid
25 375. N- (2- [exo-7-p-Fluor-phenyl-l , 5-cis-3-azabicyclo [4.3.0] non- 3-yl] -ethyl) -inden-3-carbonamid
376.1- (2- [6-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [3.3.0]oct-6-en- 3-yl] -ethyl) -naphthalin 30
377.1- (4-Fluor-phenyl) -4- [ 6-p-fluor-phenyl-1, 5-cis-3-azabicycio- [3.3.0] oct-6-en-3-yl] -butan-1-on
378. N- (2- [6-p-Fluor-phenyl-1, 5-eis-3-azabicyclo [3.3.0] oct-6-en- 35 3-yl] -ethyl) -benzamid,
379. N- (2- [6-p-Fluor-phenyl-l, 5-eis-3-azabicyclo [3.3.0] oct-6-en- 3-yl] -ethyl) -naphthalin-1-carbonamid
40 380.1- (2- [exo-6-p-Fluor-phenyl-l, 5-cis-3 -azabicyclo [3.3.0] octan- 3-yl] -ethyl) -naphthalin
381.1- (4-Fluor-phenyl) -4- [exo-6-p-fluor-phenyl-1, 5-cis-3- azabicyclo- [3.3.0] octan-3-yl] -butan-1-ol 45 382. N- (2- [exo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [3.3.0] octan- 3-yl ] -ethyl ) -benzamid
383. N- (2- [exo-6-Phenyl-l, 5-eis-3-azabicyclo [3.3.0] octan-3-yl] - 5 ethyl) -naphthalin-1-carbonamid
384. N- (2- [exo-6-Phenyl-I, 5-eis-3-azabicyclo [3.3.0] octan-3-yl] - ethyl) -inden-3-carbonamid
10 385.1- (2- [endo-6-p-Fluor-phenyl-1, 5-cis-3-azabicyclo [3.3.0] octan- 3 -yl ] -ethyl ) -naphthalin
386.1- (4-Fluor-phenyl) -4- [endo-6-p-fluor-phenyl-1, 5-cis-3- azabicyclo- [3.3.0] octan-3-yl] -butan-1-on 15
387. N- (2- [endo-6-p-Fluor-phenyl-l, 5-cis-3-azabicyclo [3.3.0] oetan-
3-yl] -ethyl) -benzamid
388. N- (2- [endo-6-Phenyl-1, 5-cis-3-azabicyclo [3.3.0] octan-3-yl] - 20 ethyl) -naphthalin-1-carbonamid
389.1- (2- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [3.3.0] octan- 3-yl] -ethyl) -naphthalin
25 390. l-(4-Fluor-phenyl)-4-[exo-7-p-fluor-phenyl-l, 5-cis-3- azabicyclo [3.3.0] octan-3-yl] -butan-1-on
391. N- (2- [exo-7-p-Fluor-phenyl-1, 5-eis-3 -azabicyclo [3.3.0] oetan-
3-yl] -ethyl) -benzamid 30
392. N- (2-[exo-7-Phenyl-l, 5-cis-3 -azabicyclo [3.3.0] octan-3-yl] - ethyl) -naphthalin-1-carbonamid
393. N- (2- [exo-7-Phenyl-1, 5-cis-3-azabicyclo [3.3.0] octan-3-yl] - 35 ethyl) -inden-3-carbonamid
394. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.1.0]hexan-3-yl] - ethyl) -4-fluor-benzamid
40 395. N- (2- [exo-6-Phenyl-3-azabicyclo[3.1.0]hexan-3-yl] -ethyl) - 5-chlor-thien-2-yl-carbonamid
396. N- (2- [6, 6-Diphenyl-3 -azabicyclo [3.1.0]hexan-3-yl] -ethyl) - naphth-1-yl-carbonamid 45 397. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.1.0]hexan-3-yl] - ethyl) -3-chlor-l-benzochien-2-yl-carbonamid
398. N- (2- [exo-6-m-Chlor-phenyl-3-azabicyclo [3.1.0]hexan-3-yl] - 5 ethyl) -4-chlor-benzamid
399.1- (2- [6-p-Fluor-phenyl-l-5-cis-8-oxa-3,7-diazabicyclo[3.3.0] - oct-6-en-3-yl] -ethyl) -naphthalin
10 400. N- (2- [6-p-Fluor-phenyl-l-5-cis-8-oxa-3,7-diazabicyclo[3.3.0]- oct-6-en-3 -yl] -ethyl ) -benzamid
401. N- (2- [6-p-Fluor-phenyl-l-5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0]- oct-6-en-3-yl] -ethyl) -naphthalin-1-carbonamid 15
402. N- (2- [6-p-Fluor-phenyl-l-5-cis-8-oxa-3, 7-diazabicyclo [3.3.0]- oct-6-en-3-yl] -ethyl ) -inden-3-carbonamid
403.1- (2- [exo/endo-6-p-Fluor-phenyl-l-5-cis-8-oxa-3 , 7-diazabi- 20 cyclo [3.3.0] octan-3-yl] -ethyl) -naphthalin
404. N- (2- [exo/endo-6-p-Fluor-phenyl-l-5-cis-8-oxa-3 , 7-diazabi- cyclo [3.3.0] octan-3-yl] -ethyl) -benzamid
25 405.1- (2- [6-Phenyl-l-5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0] oct- 6-en-3-yl] -ethyl) -naphthalin
406. N- (2- [6-Phenyl-l-5-cis-8-oxa-3 , 7-diazabicyclo [3.3.0] oct- 6-en-3-yl] -ethyl) -benzamid 30
407. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0] -heptan-3-yl] ethyl) -benzosulfonamid
408. N- (2- [exo-6-Phenyl-3-azabicyclo [3.2.0] heptan-3-y1] -ethyl ) - 35 benzosulfonamid
409. N- (2- [exo-6-p-Fluor-phenyl-3-azabicyclo- [3.2.0] -heptan- -3-yl] -ethyl) -N-methyl-benzosulfonamid
40 410. N-(2-[exo-6-(5-Chlor-thien-2-yl)-3-azabicyclo[3.2.0] - heptan-3-yl] -ethyl) -4-fluor-benzosulfonamid
411.3- [exo-6-p-Fluor-pheny1-3-azabicyclo [3.2.0]heptan-3-yl] -1- phenoxy-propan 45 412.2- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -1-p- fluor-phenoxy-ethan
413.3- [exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -1- 5 (1-naphthyloxy) -propan
414.3- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] -1-p- t-buty1-phenoxy-propan
10 415.3- [exo-6-p-Fluor-phenyl-3-azabicyclo- [3.2.0]heptan- -3-yl] -1-p-fluor-phenoxy-propan
416. N- (2- [exo-6-p-Fluor-phenyi-3-azabicyclo- [3.2.0]heptan-
-3-yl] -ethyl) -thiobenzamid 15
417. N- (2- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0] hepta -3 -yl] - ethyl) -4-fluor-thiobenzamid
418. N- (2- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - 20 ethyl) -4-chlor-thiobenzamid
419.0- (2-[exo-6-p-Fluor-phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - ethyl ) -benzoat
25 420.0- (2-[exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl-4-fluor-benzoat
421. N- (2- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] ethyl) -lH-benzo [cd] indol-2-on
30
422. N- (2- [exo-6-p-Chor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl) -lH-benzo [cd] indol-2-on
423. N- (2- [exo-6-m-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl) -lH-benzo [cd] indol-2-on
424. N- (2 -[exo-6-m-Chlor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl ) -lH-benzo [cd] indol-2 -on
40 425.3, 3-Dimethyl-l-(2- [exo-6-p-fluor-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] -ethyl) -indolinon-2
426.3 , 3-Dimethyl-l- (2- [exo-6-p-chlor-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] -ethyl) -indolinon-2 45 427.3 , 3-Dimethyl-l- (2- [exo-6-m-chlor-phenyl-3-azabicyclo [3.2.0] heptan-3-yl] -ethyl ) -indolinon-2
428.1- (2- [exo-6-p-Chlor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - 5 ethyl) -3,3, 5-trimethyl-indolinon-2
429.3 , 4-Dichlor-N- (2- [exo-6-p-nitro-phenyl-3 -azabicyclo [3.2.0] heptan-3 -yl] -ethyl ) -benzamid
10 430.2 , 5-Difluor-N- (2- [exo-6-p-fluor-phenyl-3 -azabicyclo [3.2.0] heptan-3-yl] -ethyl ) -benzamid
431.2-Amino-N- (2- [exo-6-p-fluor-phenyl-3 -azabicyclo [3.2.0 ] heptan- 3-yl] -ethyl) -benzamid 15
432.2-Amino-N- (2- [exo-6-p-chlor-phenyl-3 -azabicyclo [3.2.0] heptan-
3 -yl ] -ethyl ) -benzamid
433. N- (2- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - 20 ethyl) -2-methylamino-benzamid
434. N- (2- [exo-6-p-Chlor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl) -2-methylamino-benzamid
25 435.3-Amino-N- (2- [exo-6-p-chlor-phenyl-3 -azabicyclo [3.2.0]heptan- 3-yl] -ethyl) -benzamid
436.4-Amino-N- (2- [exo-6-p-chlor-phenyl-3 -azabicyclo [3.2.0] heptan-
3 -yl ] -ethyl ) -benzamid 30
437. N- (2- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl) -thiophen-2-carbonsäureamid
438.5-Chlor-N- (2- [exo-6-p-fluor-phenyl-3 -azabicyclo [3.2.0] heptan- 35 3-yl] -ethyl) -thiophen-2-carbonsäureamid
439.5-Chlor-N- (2- [exo-6-p-chlor-phenyl-3 -azabicyclo [3.2.0] heptan- 3-yl] -ethyl) -thiophen-2-carbonsäureamid
40 440.5-Chlor-N- (2- [exo-6- (5-chlor-2-thienyl) -3-azabicyclo [3.2.0] heptan-3-yl] -ethyl) -thiophen-2-carbonsäureamid
441. N- (2-[exo-6-p-Fluor-phenyl-3-azabicyclo[3.2.0]heptan-3-yl] - ethyl) -benzo [b] furan-2-carbonsäureamid 45 442.3-Chlor-N- (2- [exo- 6-p-fluor-phenyl -3 -azabicyclo [3.2.0 ] heptan-
3-yl] -ethyl) -benzo [b] thiophen-2-carbonsäureamid
443.3-Chlor-N- (2- [exo-6-p-chlor-phenyl-3-azabicyclo [3.2.0]heptan- 5 3-yl] -ethyl) -benzo [b] thiophen-2-carbonsäureamid
444.3-Chlor-N- (2- [exo-6-p-nitro-phenyl-3 -azabicyclo [3.2.0 ] heptan- 3-yl] -ethyl) -benzo [b] thiophen-2-carbonsäureamid
10 445. N-(2- exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] ethyl -inden-3-carbonsäureamid
446. N-(2- exo-6-p-Chlor-phenyl-3 -azabicyclo [3.2.0] heptan-3 -yl] ethyl -inden-3-carbonsäureamid
15
447. N-(2- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] ethyl -cyclopropan-carbonsäureamid
448. . N-(2- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl]
20 ethyl -cyclopentan-carbonsäureamid
449. , N-(2- exo-6-p-Chlor-phenyl-3 -azabicyclo [3.2.0] heptan-3-yl] ethyl -cyclopentan-carbonsäureamid
25 450. . N- ( 2 - exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] ethyl -cyclohexan-carbonsäureamid
451. . N-(2- exo- 6-p-Chlor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] ethyl -cyclohexan-carbonsäureamid
30
452. , N- ( 2 - exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] ethyl -naphthalin-1-carbonsäureamid
453. . N-(2- exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl]
35 ethyl -indol-2-carbonsäureamid
454. N- (2- [exo-6-p-Chlor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] -e thyl ) -indol-3-carbonsäureamid
40 455. exo-6-p-Fluorphenyl-3- [2- (1-naphthyl) -ethyl] -3 -azabicyclo [3.2.0] heptan
456. exo-6-p-Chlor-phenyl-3- [2- (1-naphthyl) -ethyl] -3-azabicyclo [3.2.0] heptan
45 457. exo-6-m-Chlor-phenyl-3- [2- (1-naphthyl) -ethyl] -3 -azabicyclo [3.2.0]heptan
458. exo-6- (5-Chlor-2-thienyl) -3- [2- ( 1-naphthyl ) -ethyl] -3-azabi- 5 cyclo [3.2.0] heptan
459. exo- 6-p-Fluor-phenyl-3- [2- (2 -naphthyl) -ethyl] -3 -azabicyclo [3.2.0]heptan
10 460. exo-6-p-Fluor-phenyl-3- [1-naphthyl-methyl] -3-azabicyclo [3.2.0]heptan
461. exo-6-p-Fluor-phenyl-3- [2-naphthyl-methyl] -3 -azabicyclo [3.2.0]heptan 15
462.4- ( 6 -p-Fluor-pheny1-3 -azabicyclo [3.2.0]heptan-3-yl) -1- (thio- phen-2-yl) -butan-1-on
463.4- ( 6-p-Chlor-phenyl-3 -azabicyclo [3.2.0] heptan-3-yl) -1- (thio- 20 phen-2-yl) -butan-1-on
464. N-(2- exo-6-p-Fluor-pheny1-3 -azabicyclo- [3.2.0] heptan-3-yl] ethyl -4-phenyl-pyrrolidinon-2
25 465. N-(2- exo-6-p-Fluor-phenyl-3-azabicycio- [3.2.0]heptan-3-yl] ethyl -benzoxazolinon-2
466. N-(2- exo-6-p-Fiuor-phenyl-3-azabicyclo- [3.2.0]heptan-3-yl] ethyl -isoindolinon
30
467. l-(2- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl -indazol
468. l-(2- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - 35 ethyl -1, 8-naphthalinsultam
469.4-(2- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl -1, 4-benzoxazin-3-on
40 470. l-(2- exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl -chinoxalin-2 ( 1H) -on
471. l-(2- exo-6-p-Fluor-phenyl-3-azabicyclo [3.2.0]heptan-3-yl] - ethyl -indolinon-2 45 472.1- (2- [exo-6-p-Fluor-phenyl-3 -azabicyclo [3.2.0]heptan-3-yl] - ethyl) -spiro [cyclopropan-1 ' , 3-indolinon-2]
473.3 , 6-Dimethyl-2-methylamino-5- [2- (exo-6- (2-naphthyl ) -3-aza- 5 bicyclo [3.2.0]heptan-3-yl) -ethyl] -3H-pyrimidin-4-on
474.3 , 6-Dimethyl-2-methylamino-5- [2- (exo-6- (1-naphthyl) -3-azabicyclo [3.2.0]heptan-3-yl) -ethyl] -3H-pyrimidin-4-on
10 475.3, 6-Dimethyl-2-methylamino-5- [2- (exo-6- (5-chlor- 1-naphthyl )- 3 -azabicyclo [3.2.0] heptan-3-yl) -ethyl] -3H-pyrimidin-4-on
476.3 , 6-Dimethyl-2-methylamino-5- [2- (exo-6- ( 6-chlor-2-naph- thyl) -3-azabicyclo [3.2.0] eptan-3-yl) -ethyl] -3H-pyrimi- 15 din-4-on
477.3 , 6-Dimethyl-2-me hylamino-5- [2- (exo-6- ( 9-phenanthryl) -3- azabicyclo [3.2.0]heptan-3-yi ) -ethyl] -3H-pyrimidin-4-on
20 478.7-Methyl-6-[2-(exo-6-(2-naphthyl)-3-azabicyclo[3.2.0]- heptan-3-yl) -ethyl) -5H-thiazolo [3 , 2-a]pyrimidin-5-on
479.3- [2- (exo-6- (2-Napthyl) -3-azabicyclo [3.2.0]heptan-3-yl) - ethyl] -1H, 3H-chinazolin-2 , 4-dion 25
480.3- [2- (exo-6- ( 1-Nap thyl) -3 -azabicyclo [3.2.0] eptan-3-yl) - ethyl] -1H, 3H-chinazolin-2 , 4-dion
481.6-Fluor-3- [2- (exo-6- (1-naphthyl) -3 -azabicyclo [3.2.0] heptan- 30 3-yl) -ethyl] -1H, 3H-chinazolin-2 , 4-dion
482.3- [2-(exo-6- (5-chlor-2-naphthyl) -3-azabicyclo [3.2.0]heptan- 3-yl) -ethyl] -1H, 3H-chinazolin-2 , 4-dion
35 483.3- [2- (exo-6- (1-Naph hyl) -3-azabicyclo [3.2.0] -heptan-3-yl) - ethyl] -2-methyl-4H-pyrido [1.2-a] -pyrimidin-4-on
484.1- [2-(exo-6- (2-Naphthyl) -3-azabicyclo [3.2.0]heptan-3-yl) - ethyl] -2 (1H) -chinolon
40
485.1- [2-(exo-6- (2 -Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - ethyl] -indolin-2-on
486.1- [2 -(exo-6-( 1-Naphthyl) -3 -azabicyclo [3.2.0] -heptan-3-yl) - 45 ethyl] -2 (3H) -benzimidazolon 487.1- [2- (exo-6- (1-Naphthyl) -3-azabicyclo [3.2.0] -heptan-3-yl ) - ethyl] -3-methyl-2 (3H) -benzimidazolon
488. N- [2-(exo-6-(l-Naphthyl) -3-azabicyclo [3.2.0]heptan-3-yl) - 5 ethyl] -benzamid
489. N- [2- (exo-6- (2-Naphthyl) -3-azabicyclo [3.2.0]heptan-3-yl) - ethyl] -benzamid
10 490. N- [2-(exo-6-(5-Chlor-l-naphthyl)-3-azabicyclo-[3.2.0] heptan-3-yl) ethyl] -benzamid
491.3- [2-(l-Naphthyl)ethyl]-exo-6- (1-naphthyl) -3-azabicyclo- [3.2.0]heptan
15
492.3- [2- (1-Naphthyl) ethyl] -exo-6- (2 -naphthyl) -3-azabi- cyclo [3.2.0] heptan
493.1- [2- (exo-6- (1-Naphthyl) -3-azabicyclo [3.2.0]heptan- 20 3-yl) ethyl] -lH-benzo [cd] indol-2-on
494.1- [2- (exo-6- (2 -Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - ethyl] -lH-benzo [cd) indol-2-on
25 495.3, 3-Dimethyl-l-[2-(exo-6-(l-naphthyl)-3-azabicyclo- [3.2.0]heptan-3-yl) ethyl] -1, 3-dihydroindol-2-on
496.3 , 3-Dimethyl-l- [2- (exo-6- (2-naphthyl) -3-azabicyclo- [3.2.0 ]heptan-3-yl) ethyl ]-l, 3-dihydroindol-2-on 30
497.3, 3-Dimethyl-l- [2- (exo-6- ( 6-chlor-2-naphthyl ) -3-azabicyclo [3.2.0]heptan-3-yl) ethyl] -1 , 3-dihydroindol-2-on
498.5-Chlor-N- [2-(exo-6- (1-naphthyl) -3 -azabicyclo- [3.2.0]- 35 heptan-3-yl) ethyl] -2-thiophencarbonsäureamid
499.5-Chlor-N- [2- (exo-6- (2-Naphthyl) -3 -azabicyclo [3.2.0] - heptan-3-yl) ethyl] -2-thiophencarbonsäureamid
40 500. N- [2 -(exo-6- (1-Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - ethyl] -4-fluor-benzamid
501. N- [2- (exo-6- (2-Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - ethyl] -4-nitro-benzamid 45 502 . N- [2 - ( exo-6- ( 6 -Chlor-2 -naphthyl ) -3 -azabicyclo [ 3 . 2 . 0] - heptan-3-yl) -ethyl] -benzamid
503. N- [2-(exo-6- (1-Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - 5 ethyl] -4-methoxy-benzamid
504. N- [2- (exo-6- (2 -Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - ethyl] -4-hydroxy-benzamid
10 505. N- [2-(exo-6-(l-Naphthyl)-3-azabicyclo[3.2.0]heptan-3-yl) - ethyl] -3 , -dichlor-benzamid
506. N- [2-(exo-6- (1-Naphthyl) -3-azabicyclo [3.2.0]heptan-3-yl) - ethyl] -naphthalin-1-carbonamid
15
507. N- [2-(exo-6- (2-Naphthyl) -3-azabicyclo [3.2.0]heptan-3-yl) - ethyl] -naphthalin-1-carbonamid
508. N- [2- (exo-6- ( 9-Phenanthryl) -3-azabicyclo [3.2.0]heptan- 20 3-yl) -ethyl] -benzamid
509.1- [2-(exo-6- ( 6-Chlor-2 -naphthyl) -3 -azabicyclo-
[3.2.0]heptan-3-yl) -ethyl] -lH-benzo [cd] indol-2-on
25 510.1- [2- (exo-6-(9-Phenanthryl)-3-azabicyclo-
[3.2.0]heptan-3-yl) -ethyl] -lH-benzo [cd] indol-2-on
511. N- [2-(exo-6- (1-Naphthyl) -3-azabicyclo [3. .0]heptan-3-yl) - ethyl] -isoindolinon
30
512. N- [2-(exo-6- (2-Naphthyl) -3 -azabicyclo [3.2.0]heptan-3-yl) - ethyl] -isoindolinon
513. (+ )-(lS, 5R, 6S)-exo-l- [2- [6- (4-Chlor-phenyl) -3-azabicyclo- 35 [3.2.0]heptan-3-yl] -ethyl] -3-methyl-2H-l, 3-dihydro-benz- imidazol-2-on
514. (+)- (IS, 5R, 6S) -exo-l-[2- [6- (4-Chlor-phenyl) -3-azabicyclo- [3.2.0]heptan-3-yl] -ethyl] -3-ethyl-2H-l, 3-dihydro-benz-
40 imidazol-2-on
515. (+)- (IS, 5R, 6S) -exo-1- [2- [6- (4-Chlor-phenyl) -3-azabicyclo- [3.2.0]heptan-3-yl] -ethyl] -3-n-propyl-2H-l, 3-dihydro-benz- imidazol-2-on
45 516. (4-)- (IS, 5R, 6S) -exo-2-[2- [6- (4-Chlor-phenyl ) -3-azabicyclo-
[3.2.0]heptan-3-yl] -ethyl] -3 , 3-dimethyl-2 , 3-dihydro-l, 2-benz- isothiazol-1, 1-dioxid
5 517. (4-) -(IS, 5R,6S)-exo-2-[2- [6- ( 4-Chlor-phenyl) -3-azabicyclo- [3.2.0]heptan-3-yl] -ethyl] -2 , 3-dihydro-l, 2-benzisothiazol- 1, 1-dioxid
518. (4-)- (IS, 5R, 6S) -exo-2- [2- [6- ( 4-Fluor-phenyl ) -3-azabicyclo- 0 [3.2.0]heptan-3-yl] -ethyl] -3 , 3-dimethyl-2 , 3-dihydro-l, 2-benz- isothiazol-1, 1-dioxid
519. (4-) - (IS, 5R, 6S) -exo-2-[2- [6- (4-Fluor-phenyl) -3-azabicyclo-
[3.2.0]heptan-3-yl] -ethyl] -3 , 3-diethyl-2 , 3-dihydro-l, 2-benz- 5 isothiazol-1, 1-dioxid
520. (4-)- (IS, 5R, 6S) -exo-2-[2- [6- (4-Fluor-phenyl ) -3-azabicycio- [3.2.0]heptan-3-yl] -ethyl] -2 , 3-dihydro-l, 2-benzisothiazol- 1, 1-dioxid 0
5
0
5
0
5

Claims

Patentansprüche
1. Verwendung von N-substituierten 3 -Azabicycloalkan-Derivaten der Formel I
Figure imgf000043_0001
worin
B ein 4-, 5- oder 6-Ring ist, der eine Doppelbindung enthalten kann, ist,
R1 eine gegebenenfalls durch Halogenatome, Cι_4-Alkyl,
Trifluormethyl- , Hydroxy-, Cι_ -Alkoxy- , Amino-, Mono- methylamino-, Dimethylamino- , Cyano- oder Nitrogruppen mono- oder disubstituierte Phenyl-, Naphthyl-, Phen- anthryl-, oder Thienylgruppe bedeutet,
n die Zahl 0, 1, 2, 3 oder 4 bedeutet und
R2 eine gegebenenfalls durch ein oder zwei Halogenatome substituierte Naphthylgruppe oder einen der folgenden Reste bedeutet:
Figure imgf000043_0002
Figure imgf000044_0001
worin
R3 ein Wasserstoffatom, eine Hydroxygruppe oder einen gegebenenfalls durch ein Fluor-, Chlor- oder Bromatom substituierten Phenylrest darstellt,
R4 ein Wasserstoffatom bedeutet oder
R3 und R4 zusammen ein Sauerstoffatom darstellen,
R5 eine gegebenenfalls durch Fluor-, Chlor- oder Bromatome oder Hydroxy-, Nitro-, Amino-, Cι_4-Alkanoylamino-, Cι-4-Alkylamino-, Cι-4-Alkyl- oder Methoxygruppen mono- oder disubstituierte Phenyl-, Naphthyl- oder Thienyl- gruppe bedeutet,
R6 ein Wasserstoffatom oder eine Methylgruppe darstellt,
R7 eine durch Fluor-, Chlor- oder Bromatome oder durch Cι_4-Alkyl-, Hydroxy-, Methoxy-, Nitro-, Cyano-, Tri- fluormethyl-, Amino- oder Di-Cι_4-Alkylaminogruppen mono- oder disubstituierte Phenyl-, Naphthyl-, Benzofuryl-, Benzothienyl- , Thienyl-, Indolyl-, N-Methylindolyl- oder Indenylgruppe oder eine C_ -Cycloalkylgruppe bedeutet, R8 ein Wasserstoffatom oder ein Fluor- oder Chloratom oder eine Cι_4-Alkyl-, Methoxy- oder Aminogruppe ist,
R9 ein Wasserstoffatom oder eine Methylgruppe darstellt und
R10 ein Wasserstoffatom oder eine Methylgruppe oder
R9 und R10 zusammen mit dem Ring-Kohlenstoffatom einen Spiro- cyclopropanring darstellen,
R11 ein Wasserstoffatom, eine Hydroxy-, Cι-C4~Alkyl- oder Cι~C4-Alkoxygruppe ist, oder zusammen mit dem benachbarten Kohlenstoffatom eine C=0- oder C=S-Gruppe bedeutet,
X und Y Kohlenstoffatome, CH-, CH2-, NH- oder Cι-C-Alkyl- N-Gruppen oder Stickstoffatome bedeuten,
Z eine direkte Bindung, eine CO-Gruppe, CS-Gruppe oder eine CH- bzw. CH2-Gruppe, in denen ein Wasserstoffatom gegen eine Hydroxy-, Amino- oder Cι-C4~Alkoxygruppe oder ein Halogenatom ausgetauscht sein kann, darstellt, und
A ein Wasserstoffatom, eine Hydroxy-, Amino-, Mercapto-, Cι-C-Alkylamino-, Di-Cι-C-alkylamino-, Cι-C4-Alkylthio- oder Cι_-C4-Alkoxygruppe oder zusammen mit dem benachbarten Kohlenstoffatom eine C=0-Gruppe bedeutet, oder
A eine mit Y verknüpfte C3-C4-Alkylengruppe bedeutet, die eine oder zwei nicht kumulierte Doppelbindungen enthalten kann und in der eine CH- oder CH2-Gruppe durch ein Stickstoff- oder Schwefelatom oder eine NH- oder N-CH-Gruppe ersetzt sein kann und wobei der Ring entweder durch ein Fluor- oder Chloratom oder eine Methyl-, Methoxy-, Nitro- oder Aminogruppe monosubstituiert oder im Fall eines
Benzolrings dieser durch Fluor- oder Chloratome oder Methyl-, Trifluormethyl-, Nitro-, Hydroxy-, Methoxy-, Amino-, Monomethyl- oder Dimethylaminogruppen mono-, di- oder trisubstituiert sein kann,
und worin der X, Y und Z enthaltende Ring am Stickstoffatom Nr. 1 eine Cι-C4-Alkyl-, Allyl- oder Benzylgruppe tragen und 1 bis 3 nicht kumulierte Doppelbindungen enthalten kann, und deren Salze mit physiologisch verträglichen Säuren
zur Herstellung von Arzneimitteln zur Behandlung von Erkrankungen des zentralen Nervensystems..
2. Verwendung nach Anspruch 1 zur Herstellung von Arzneimitteln zur Behandlung von Suchterkrankungen.
3. Verwendung nach Anspruch 1 oder 2 zur Herstellung von Arznei- mittein zur Bekämpfung der Cocain-Sucht .
4. Verwendung nach Anspruch 1 oder 2 zur Herstellung con Arzneimitteln zur Bekämpfung der Sucht nach Amphetaminen und amphetaminartigen Substanzen.
PCT/EP1999/008734 1998-11-24 1999-11-12 Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems WO2000030639A1 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA002352526A CA2352526A1 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
IL14318199A IL143181A0 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
AU17753/00A AU1775300A (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
PL99348758A PL348758A1 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
SK711-2001A SK7112001A3 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
BR9915589-3A BR9915589A (pt) 1998-11-24 1999-11-12 Uso de derivados de azabicicloalcano n-substituìdo
EP99960974A EP1133293A1 (de) 1998-11-24 1999-11-12 Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems
HU0104416A HUP0104416A3 (en) 1998-11-24 1999-11-12 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system and medicaments containing the compounds
KR1020017006445A KR20010080535A (ko) 1998-11-24 1999-11-12 중추신경계 질환의 치료를 위한 ｎ-치환 아자비시클로알칸유도체의 용도
JP2000583522A JP2002530333A (ja) 1998-11-24 1999-11-12 中枢神経系障害の治療用薬剤を製造するためのｎ−置換３−アザビシクロアルカン誘導体使用
NO20012538A NO20012538L (no) 1998-11-24 2001-05-23 Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet
BG105549A BG105549A (en) 1998-11-24 2001-05-30 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
HR20010472A HRP20010472A2 (en) 1998-11-24 2001-06-21 Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system
HK02102768.4A HK1040933A1 (zh) 1998-11-24 2002-04-12 N-取代的氮雜二環烷衍生物在治療中樞神經系統疾病中的應用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19854147.3 1998-11-24
DE19854147A DE19854147A1 (de) 1998-11-24 1998-11-24 Verwendung von N-substituierten Azabicycloalkan-Derivaten zur Verwendung bei der Bekämpfung der Cocainsucht

Publications (1)

Publication Number Publication Date
WO2000030639A1 true WO2000030639A1 (de) 2000-06-02

Family

ID=7888824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008734 WO2000030639A1 (de) 1998-11-24 1999-11-12 Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems

Country Status (21)

Country Link
EP (1) EP1133293A1 (de)
JP (1) JP2002530333A (de)
KR (1) KR20010080535A (de)
CN (1) CN1328455A (de)
AR (1) AR021502A1 (de)
AU (1) AU1775300A (de)
BG (1) BG105549A (de)
BR (1) BR9915589A (de)
CA (1) CA2352526A1 (de)
CZ (1) CZ20011796A3 (de)
DE (1) DE19854147A1 (de)
HK (1) HK1040933A1 (de)
HR (1) HRP20010472A2 (de)
HU (1) HUP0104416A3 (de)
IL (1) IL143181A0 (de)
NO (1) NO20012538L (de)
PL (1) PL348758A1 (de)
SK (1) SK7112001A3 (de)
TR (1) TR200101476T2 (de)
WO (1) WO2000030639A1 (de)
ZA (1) ZA200103976B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589363A1 (en) 2004-12-13 2006-06-22 Eli Lilly And Company Spiro derivatives as lipoxygenase inhibitors
GB0812310D0 (en) 2008-07-03 2008-08-13 Syngenta Ltd Novel herbicides
MX2015009153A (es) * 2013-01-15 2016-03-04 Novartis Ag Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004311A1 (en) * 1987-11-12 1989-05-18 American Home Products Corporation Polycyclicamines with psychotropic activity
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
DE4427648A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004311A1 (en) * 1987-11-12 1989-05-18 American Home Products Corporation Polycyclicamines with psychotropic activity
DE4341403A1 (de) * 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
WO1995015327A1 (en) * 1993-12-04 1995-06-08 Basf Aktiengesellschaft N-substituted azabicycloalkane derivatives as neuroleptika asf
DE4427648A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
DE4427647A1 (de) * 1994-08-04 1996-02-08 Basf Ag N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
WO1996004272A1 (de) * 1994-08-04 1996-02-15 Basf Aktiengesellschaft N-substituierte 3-azabicyclo(3.2.0)heptan-derivate als neuroleptika
US5753690A (en) * 1994-08-04 1998-05-19 Basf Aktiengesellschaft N-substituted azobicycloheptane derivatives, the preparation and use thereof

Also Published As

Publication number Publication date
CZ20011796A3 (cs) 2002-05-15
TR200101476T2 (tr) 2001-10-22
BG105549A (en) 2001-12-29
CA2352526A1 (en) 2000-06-02
CN1328455A (zh) 2001-12-26
HUP0104416A2 (hu) 2002-04-29
HRP20010472A2 (en) 2003-04-30
BR9915589A (pt) 2001-08-07
HUP0104416A3 (en) 2002-11-28
EP1133293A1 (de) 2001-09-19
NO20012538D0 (no) 2001-05-23
AU1775300A (en) 2000-06-13
SK7112001A3 (en) 2001-12-03
NO20012538L (no) 2001-07-04
JP2002530333A (ja) 2002-09-17
IL143181A0 (en) 2002-04-21
DE19854147A1 (de) 2000-05-25
PL348758A1 (en) 2002-06-03
AR021502A1 (es) 2002-07-24
HK1040933A1 (zh) 2002-06-28
ZA200103976B (en) 2002-05-16
KR20010080535A (ko) 2001-08-22

Similar Documents

Publication Publication Date Title
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
KR101455947B1 (ko) 글리신 수송 억제제 화합물과 항정신병약의 조합물
US20040029860A1 (en) Anti-proliferative drugs
KR20160005341A (ko) Ampk 활성인자 및 세로토닌성 제제를 포함하는 약학 조성물 및 이의 사용 방법
US20060293309A1 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
CA1331139C (en) Medicaments for the treatment of cerebral apoplexy
US20110172251A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2004504376A (ja) 医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ
ES2683184T3 (es) Inhibidores de GLyT1 para su uso en el tratamiento de trastornos hemáticos
JPH10507777A (ja) ドパミン系の障害を治療するためのフェノキシピペラジン誘導体
JPH0733332B2 (ja) 痴呆症状改善・治療剤
US20030235631A1 (en) Combination treatment for depression and anxiety
EP0759299A1 (de) Potenzierung von Serotonin-Wirkstoffresponz
WO2018148737A1 (en) 5-ht2a serotonin receptor serotonin receptor inverse agonists useful for the prophylaxis and treatment of parkinsonian symptoms associated with a neurodegenerative disease
AU619420B2 (en) Treatment of depression
WO2000030639A1 (de) Verwendung von n-substituierten azabicycloalkan-derivaten zur behandlung von erkrankungen des zentralen nervensystems
ES2267943T3 (es) Metodos de uso de derivados pirrolicos contra el trastorno obsesivo compulsivo.
US20090291939A1 (en) Treating Alcohol And Or Substance Abuse By Antagonizing Alpha 2 Adrenergic Receptors With Weak Dopamine Blocking
ZA200209272B (en) Aromatic polyurethane polyol.
NL8002041A (nl) Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel.
Madhusoodanan et al. Use of olanzapine for elderly patients with psychotic disorders: a review
US6221858B1 (en) Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders
Ehret et al. Focus on lurasidone: A new atypical antipsychotic for the treatment of schizophrenia.
US3505451A (en) Compositions and methods for alleviating schizophrenia employing one of haloperidol,trifluperidol or an acid addition salt thereof and one of desipramine,imipramine and an acid addition salt thereof
Mack et al. Focus on... Eszopiclone

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99813559.3

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 17753

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001/03976

Country of ref document: ZA

Ref document number: 143181

Country of ref document: IL

Ref document number: 200103976

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1999960974

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 511822

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005104

Country of ref document: MX

Ref document number: PV2001-1796

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2352526

Country of ref document: CA

Ref document number: 2352526

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 7112001

Country of ref document: SK

Ref document number: 1020017006445

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 583522

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/717/CHE

Country of ref document: IN

Ref document number: 2001/01476

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 1999 105549

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 17753/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: P20010472A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 09856293

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1020017006445

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999960974

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1796

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999960974

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017006445

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-1796

Country of ref document: CZ